Precigen, Inc. (NASDAQ:PGEN - Get Free Report)'s stock price traded up 7.8% during trading on Friday . The company traded as high as $1.69 and last traded at $1.73. 1,712,647 shares were traded during mid-day trading, a decline of 15% from the average session volume of 2,010,455 shares. The stock had previously closed at $1.60.
Analyst Ratings Changes
A number of equities research analysts have commented on the company. JMP Securities restated a "market outperform" rating and issued a $5.00 target price on shares of Precigen in a research report on Tuesday, January 14th. HC Wainwright reaffirmed a "buy" rating and set a $6.00 price objective (up from $4.00) on shares of Precigen in a research report on Thursday, January 23rd. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $7.00.
Get Our Latest Research Report on PGEN
Precigen Trading Down 4.5 %
The firm has a 50 day simple moving average of $1.07 and a two-hundred day simple moving average of $1.03. The company has a market capitalization of $497.88 million, a PE ratio of -3.09 and a beta of 1.66.
Institutional Trading of Precigen
Hedge funds have recently modified their holdings of the business. Fore Capital LLC raised its holdings in Precigen by 27.7% during the fourth quarter. Fore Capital LLC now owns 391,811 shares of the biotechnology company's stock worth $439,000 after purchasing an additional 85,000 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Precigen by 4.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,278,862 shares of the biotechnology company's stock valued at $1,432,000 after purchasing an additional 56,012 shares during the period. Rhumbline Advisers grew its position in shares of Precigen by 7.3% in the fourth quarter. Rhumbline Advisers now owns 197,134 shares of the biotechnology company's stock valued at $221,000 after purchasing an additional 13,338 shares during the period. Stoneridge Investment Partners LLC grew its position in Precigen by 21.3% during the fourth quarter. Stoneridge Investment Partners LLC now owns 68,681 shares of the biotechnology company's stock valued at $77,000 after acquiring an additional 12,063 shares during the period. Finally, Iridian Asset Management LLC CT grew its position in Precigen by 38.8% during the fourth quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company's stock valued at $5,871,000 after acquiring an additional 1,465,962 shares during the period. 33.51% of the stock is owned by institutional investors and hedge funds.
About Precigen
(
Get Free Report)
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
Further Reading
Before you consider Precigen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.
While Precigen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
